Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

PlanetiQ’s Radio Occultation Data Rated “Best-in-Class” by NASA CSDA biomodal publishes study in Nature Communications Medicine highlighting breakthrough in earlier colorectal cancer detection Antevia Networks deploys 5G private network at Bath Rugby stadium Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases Paragraf produces first 6-inch graphene wafer at new Huntingdon facility Long Wall announces Cyclops: the mass-producible interceptor
Back To News
Ventyx Biosciences
June 6, 2020

Ventyx Biosciences

Developing selective inhibitors of TYK2 for autoimmune diseases.

Cookie Policy Website powered by 100% renewable energy Privacy Policy